New PET scan agent aims to spot cancers more precisely
NCT ID NCT07552467
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new radioactive imaging agent that targets a protein called LRRC15, found on many cancer cells. Researchers will use PET scans to see if this agent can better detect and stage cancers like pancreatic, breast, lung, and others. The trial includes 26 healthy volunteers and cancer patients to check safety and how the agent spreads in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LRRC15-targeted PET radiotracer (diagnostic imaging agent)
- What this could lead to
- If successful, this could provide a more accurate way to diagnose and stage several types of cancer, helping doctors choose better treatments.
- What could go wrong
- This is an early-phase study with only 26 participants, so results may not apply broadly. The imaging agent's safety and effectiveness are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Union Hospital, China
RECRUITINGWuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a plasma beam stop colon polyps from coming back?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- A stitch in time: could a device make abdominal closure safer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts